- Consultant gynaecological oncologist at the UCLH Gynaecological Cancer Centre since 2000.
- Subspeciality training at University College London Hospital, St Bartholomew's Hospital London, Royal Marsden Hospital London.
- Member of British Gynaecological Cancer Society, British Society Colposcopy and Cervical Pathology, European Society of Gynaecological Oncologists, International Gynaecological Cancer Society.
- Honorary senior lecturer, with over 30 peer reviewed publications, and 10 book chapters.
- Trial management committee for the United Kingdom collaborative trial in ovarian cancer screening.
Tim Mould underwent undergraduate training at Oxford University and St Thomas Hospital medical school before going on to post graduate obstetric and gynaecology training at St Thomas’, Queen Charlotte’s & Chelsea, University College and the Whittington Hospitals.
He completed RCOG sub specialist gynaecological cancer training at Barts and the Royal Marsden Hospitals before returning to UCH as a consultant gynaecological oncologist in 2000.
He has RCOG sub-specialist accreditation in gynaecological cancer, colposcopy and minimal access surgery. Since 2000, he has had roles as lead for gynaecological cancer at UCLH, North London Cancer Network lead for gynaecological cancer, lead for colposcopy at UCLH, divisional clinical director Women’s Health UCLH. At present, he is pathway director for gynaecology for London Cancer
- Ovarian cancer
- Endometrial cancer
- Cervical cancer
Menon U, Gentry-Maharaj A, Hallet R, Ryan et al (2009), Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Lancet Oncology, vol 10 (4), p 327-340
ASTEC study group, Kitchener H, Swart A, Qian Q, Amos C, Parmar M (2009)
Efficacy of systemic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
Lancet, vol 373, p125-36
Apostolidou S, Hadwin R, Burnell M et al (2009), DNA methylation analysis in liquid based cytology for cervical cancer screening. Int J Cancer 2009 Dec 15;125(12):2995-3002
Raza A, Mould T, Wilson M, et al (2010), Increasing the effectiveness for referral of ovarian masses from cancer unit to cancer centre by using a higher referral value of the Risk Malignancy Index", Int J Gynecol Cancer. 2010 May;20(4):552-4
Fallowfield L, Fleissig A, Barrett J, Menon U, Jacobs I, Kilkerr J, Farewell V; UKCTOCS Trialists. (2010) Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening., Br J Cancer. 2010 Aug 10;103(4):454-61
Jacobs I, Gentry-Maharaj A, Burnell et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort., Lancet Oncol. 2011 Jan;12(1):38-48.
Burnell M, Gentry-Maharaj A, Ryan A, et al. Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. Trials. 2011 Mar 1;12:61
Sharma A, Gentry-Maharaj A, Burnell M et al. Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. BJOG. 2012 Jan;119(2):207-19.
Saha A, Varughese M, Gallagher CJet al Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.Int J Gynecol Cancer. 2012 May;22(4):566-72
Sharma A, Apostolidou S, Burnell M, et al. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).Ultrasound Obstet Gynecol. 2012 Sep;40(3):338-44
Iyer R, Gentry-Maharaj A, Nordin A, et al. Patient-reporting improves estimates of postoperative complication rates: a prospective cohort study in gynaecological oncology. Br J Cancer. 2013 Aug 6;109(3):623-32
Jones A, Teschendorff AE, Li Q, Hayward JD, et al. Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development.PLoS Med. 2013 Nov;10(11):
Doufekas K, Hadwin R, Kandimalla R, et al. GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer.Int J Gynecol Cancer. 2013 Jul;23(6):1050-5..
Iyer R, Gentry-Maharaj A, Nordin A, et al.Predictors of complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC-UK gynaecological oncology surgical outcomes and complications). Br J Cancer. 2014 Dec 23. doi: 10.1038/bjc.2014.630